TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TuHURA Biosciences (NASDAQ:HURA) reported third-quarter financial results and preliminary tumor responses in its first three IFx-2.0 study patients. Each patient had an objective partial response ongoing for more than six months with IFx-2.0 plus Keytruda in metastatic Merkel cell carcinoma. FDA clearance permits a Phase 1b TBS-2025 study in previously treated, relapsed or refractory mutNPM1 acute myeloid leukemia.
At September 30, 2026, cash was $1.9 million. Quarterly research and development expenses fell to $3.7 million from $5.0 million a year earlier; administrative expenses rose to $2.0 million from $1.6 million. Nine-month operating cash outflows narrowed to $18.1 million from $22.1 million. TuHURA received $5.6 million from its Parkview loan facility during the quarter. The company expects preliminary TBS-2025 safety and response data in the first half of 2027 and completion of IFx-2.0 Phase 3 enrollment in the second half.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointIFx-2.0 plus Keytruda produced preliminary partial responses in all first 3 patients, ongoing beyond six months.
- Moderate pointTBS-2025 received FDA clearance for Phase 1b evaluation in relapsed/refractory mutNPM1 acute myeloid leukemia.
- Moderate pointParkview loan facility provided $5.6 million in non-dilutive financing during the third quarter of 2026. 6.1% of market cap
- Moderate pointResearch and development expenses fell $1.3 million to $3.7 million in Q3 2026 versus Q3 2025.
- Moderate pointNine-month operating cash outflows narrowed to $18.1 million from $22.1 million in the comparable 2025 period.
10 minor points
- Minor pointNine-month financing cash inflows rose to $16.5 million from $13.4 million in the comparable 2025 period.
- Minor pointTBS-2025 patent expands antibody and treatment coverage, with a term extending to 2042 before potential extensions.
- Minor pointDOR technology patent covers uses beyond antibody-drug conjugates, with a term through 2043 before extensions.
- Minor point. Forward-looking: it has not happened yet and may not happen.IFx-2.0 orphan drug designation in Merkel cell carcinoma is expected in 2H 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.IFx-2.0 deep-seated tumor study preliminary results are expected in 1H 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.IFx-2.0 Phase 3 enrollment completion is expected in 2H 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.TBS-2025 Phase 1b/2 trial initiation is expected in 2H 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.TBS-2025 orphan drug designation in acute myeloid leukemia is expected in 1H 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.TBS-2025 preliminary safety and response data are expected in 1H 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Antibody-drug conjugate animal proof-of-concept studies are anticipated to begin in 2H 2026.
Negative
- Moderate pointParkview credit facility borrowings provided $9.2 million in gross proceeds through September 30, 2026, adding debt. 10% of market cap
- Minor pointGeneral and administrative expenses rose $0.4 million to $2.0 million in Q3 2026 versus Q3 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Manufacturing costs are expected to resume next quarter with the TBS-2025 clinical material manufacturing campaign.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential TBS-2025 trial expansion discussions with FDA depend on encouraging dose-optimization response rates.
News Explained
TuHURA reports continuing access to a
Key Figures
- Patients with ongoing responses
- 3 patients; more than six months
- Preliminary IFx-2.0 study; each of the first three patients had a response
- Cash and cash equivalents
- $1.9 million
- At September 30, 2026
- Parkview facility financing
- $5.6 million
- Non-dilutive financing during the quarter ended September 30, 2026
- Parkview facility gross proceeds
- $9.2 million
- Received as of September 30, 2026
- Research and development expenses
- $3.7 million vs. $5.0 million
- Three months ended September 30, 2026 and 2025, respectively
- General and administrative expenses
- $2.0 million vs. $1.6 million
- Three months ended September 30, 2026 and 2025, respectively
- Net cash outflows from operating activities
- ($18.1) million vs. ($22.1) million
- Nine months ended September 30, 2026 and 2025, respectively
- Net cash flows from financing activities
- $16.5 million vs. $13.4 million
- Nine months ended September 30, 2026 and 2025, respectively
Previous Earnings Reports
-
Prior quarter established the $50 million Parkview facility and anticipated runway into 2028.
-
Prior Q3 disclosed nine-month operating cash outflows, enabling a same-period comparison with this report.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
relapsed/refractory medical
orphan drug designation regulatory
accelerated approval regulatory
antibody drug conjugate technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
"We continue to make significant progress across each of our programs. In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda® in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months," said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "Working collaboratively with the FDA, we received clearance to begin our Phase 1b study of TBS-2025, our VISTA-inhibiting antibody, in relapsed/refractory mutNPM1 acute myeloid leukemia (AML), a molecularly defined subset of AML where the presence of VISTA on leukemic cells is associated with poor response to therapy and survival."
Dr. Bianco continued, "We will have a strong presence again this year at the upcoming American Society of Hematology (ASH) Annual Meeting in December with 3 poster presentations highlighting our Delta Opioid Receptor (DOR) technology. The ASH scientific review committee recognized the importance of our discoveries of the central role the DOR plays in controlling proliferation, recruitment and immunosuppressive capabilities of MDSCs, the body's main cell type for suppressing immune responses leading to acquired resistance to cancer immunotherapies."
"With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a
Third Quarter and Recent Corporate Highlights:
- Announced three poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 12-15, 2026, in
New Orleans . The posters highlight research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of myeloid-derived suppressor cells (MDSCs), and the data underscore the potential therapeutic breadth of DOR technology across MDSCs, T regs and M2 macrophages.
- Provided a first look at data from its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda® in first line treatment of patients with deep seated metastatic Merkel Cell Carcinoma. Preliminary results demonstrated major objective partial responses in each of the first 3 patients, constituting major objective tumor responses, which are ongoing for more than six months.
- Received a new
U.S . Patent broadening coverage for its VISTA Inhibitor, TBS-2025. The patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies as well as coverage for methods of treatment that extend beyond cancer, expanding into new treatment areas like autoimmune disease and infection. The patent term extends to 2042, prior to any potential patent term adjustment and/or regulatory patent term extension.
- Received key
U.S . patent for its groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) technology. The patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies. The term of the patent runs through 2043 before any patent term extension.
- Well funded to achieve clinical goals. The Parkview loan facility contributed
$5.6 million
- Received FDA "Study May Proceed" notice and IND clearance for the evaluation of its VISTA-Inhibiting Antibody in molecularly defined subsets of AML and other blood-related cancers. The IND allows the Company to examine TBS-2025 in a Phase 1b study evaluating the safety and potential efficacy of monotherapy at different doses in patients with relapsed/refractory (r/r) mutNPM1 AML who have failed to respond to or relapsed after Menin inhibitor therapy. If TBS-2025 results in encouraging response rates during the dose-optimization stage of the study, the Company will explore with the FDA the potential expansion of the trial in consideration for the opportunity for accelerated approval.
Currently Anticipated Milestones by Program
IFx-2.0 (Innate Immune Agonist)
- 2H 2026: Expect to receive orphan drug designation in MCC
- 1H2027: Expect preliminary results from front-line study IFX-2.0 with Keytruda® when administered by CT or ultrasound-guided techniques to metastatic deep seated MCC
- 2H 2027: Expect to complete enrollment in the Company's Phase 3 registrational front-line study of IFx-2.0 as adjunctive therapy to Keytruda® in advanced or metastatic MCC
TBS-2025 (VISTA inhibiting mAb)
- 2H 2026: Expect to initiate a Phase 1b/2 trial of TBS-2025 VISTA inhibiting antibody in mutNPM1 r/r AML
- 1H 2027: Expect to receive orphan drug designation in AML
- 1H 2027: Expect preliminary safety and response data for VISTA in mutated NMP1 r/r AML
MDSC Inhibitors (Bi-specific ADCs)
- 2H 2026: Presentations at ASH
- 2H 2026: Initiation of ADC in vivo POC studies
Summary of Financial Results for the Third Quarter 2026
Cash and cash equivalents of
Research and development expenses were
General and administrative (G&A) expenses were
Net cash outflows from operating activities were
Net cash flows from financing activities were
Total common shares outstanding were approximately 65.8 million at September 30, 2026.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA is developing TBS-2025, its VISTA-inhibiting mAb in a Phase 1b clinical trial in patients with mutNPM1 r/r AML, a molecularly defined subgroup that represents approximately
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely," or the negative or plural of these words or similar expressions. Our statements in this press release regarding our ongoing research programs and studies are an example of such forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, among others, the risk that funds available under the Company's credit facility may be insufficient to fund the Company's operations and development programs to the extent anticipated; risks associated with conducting the ongoing Phase 3 trial for IFx.20; the risks associated with continuing the development of TBS-2025 and our DOR technologies and our planned Phase 1b trial for TBS-2025; risks related to patient enrollment, trial design, data outcomes and regulatory interactions; uncertainty regarding the timing and likelihood of milestones and regulatory approvals; and the other risks described from time to time in detail in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed on March 31, 2026, and TuHURA's other reports and filings with the SEC from time to time, which are available on TuHURA's website and at www.sec.gov.
The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-reports-third-quarter-2026-financial-results-and-provides-a-corporate-update-302938454.html
SOURCE TuHURA Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TuHURA's preliminary IFx-2.0 study results show?
The first 3 patients each had an objective partial response ongoing for more than six months. The open-label study evaluates IFx-2.0 alongside Keytruda as first-line treatment for patients with deep-seated metastatic Merkel cell carcinoma. These are preliminary results.
Who is eligible for TuHURA's cleared TBS-2025 Phase 1b study?
The study will evaluate patients with relapsed or refractory mutNPM1 acute myeloid leukemia who did not respond to, or relapsed after, Menin inhibitor therapy. It will assess the safety and potential efficacy of TBS-2025 used alone at different doses.
Why did TuHURA's third-quarter research and development expenses decline?
Research and development expenses declined because of lower manufacturing costs. Those costs are expected to resume in the next quarter as the TBS-2025 clinical trial material manufacturing campaign begins.